Detection and Quant of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using Positron Emission Tomography/Computed Tomography (PET/CT)
This trial is active, not recruiting.
|Treatments||fludeoxyglucose f18, computed tomography, positron emission tomography|
|Sponsor||Abramson Cancer Center of the University of Pennsylvania|
|Start date||May 2009|
|End date||July 2013|
|Trial size||10 participants|
|Trial identifier||NCT01004718, NCI-2009-01348, UPCC 21408|
RATIONALE: Imaging procedures, such as positron emission tomography or computed tomography, may help in detecting differences between Hodgkin lymphoma or diffuse large B-cell lymphoma cancer cells. PURPOSE: This clinical trial is studying positron emission tomogaphy and computed tomography in determining differences in Hodgkin lymphoma and diffuse large B-cell lymphoma.
|Endpoint classification||efficacy study|
|Intervention model||single group assignment|
Amount of lesional FDG uptake (assessed by qualitative assessment, standardized uptake value (SUV), and lesion to background uptake ratios)
time frame: At 60 and 180 minutes after FDG administration
Rate of change of lesional FDG uptake (measured by change in SUV)
Characteristics of lesional SUV frequency histograms (e.g., mean, standard deviation, full-width-half-maximum (FWHM), etc.) and/or lesional SUV heterogeneity maps, along with changes in these characteristics
Effect of lesion size (e.g., lesions = 3 cm) on primary outcome variables.
Effect of lesion location on primary outcome variables (e.g., nodal vs extranodal)
Effect of imaging delay time of PET image acquisition upon number of lymphomatous lesions detected
Male or female participants at least 18 years old.
- Subjects with a pathologically-proven diagnosis of classic HL or DLBCL with measurable disease by any imaging technique or physical examination.
- Pregnant or nursing,
- Uncontrolled diabetes mellitus,
- Active infection,
- Inability to give informed consent or to comply with all study procedures,
- Subjects may be excluded at the discretion of the principal investigator or study team members.
|Official title||A Pilot Study to Assess the Feasibility of Detection and Quantification of Differences in Hodgkin Lymphoma and Diffuse Large B-cell Lymphoma Using FDG-PET/CT Imaging|
|Description||OBJECTIVES: I. Assess the feasibility of detection and quantification of differences in the temporal and spatial distribution of FDG uptake between lesions of HL and DLBCL. OUTLINE: Patients undergo fludeoxyglucose F18 (FDG) positron emission tomography/computed tomography scans 60 and 180 minutes after FDG administration. After completion of study, patients are followed for 24 hours.|
Call for more information